Moteur de recherche d’entreprises européennes
Financement de l’UE (9 862 546 €) : Génération du prototype CanPath - une plateforme pour la modélisation prédictive des voies du cancer Hor01/03/2016 Programme de recherche et d'innovation de l'UE « Horizon »
Vue d’ensemble
Texte
Génération du prototype CanPath - une plateforme pour la modélisation prédictive des voies du cancer
Recent developments in omics technologies demand implementation of systems biology approaches to facilitate analysis and interpretation of the generated complex datasets.This is essential for biotechnological as well as preclinical and clinical applications. In comparison to previous approaches, most cancer relevant studies are confined to pattern recognition or at best modelling of single pathways, rather than the complex pathways and cross-talk determining cancer progression and drug response. Systematic tools that evaluate and validate personalised medicine approaches on a preclinical level are missing; an important prerequisite for translation into clinical practice. The overall objective of CanPathPro is to build and validate a new biotechnological application: a combined experimental and systems biology platform, which will be utilized in testing cancer signaling hypotheses in biomedical research and life sciences. Thus, the proposed project will focus on developing and refining bioinformatic and experimental tools for the evaluation of systems biology modelling predictions. Components comprise a highly controlled mouse experimental system, NGS, a quantitative proteomics based read-out of changes in pathway signalling and an integrative systems biology model for data integration. Testable hypotheses about biological systems will be generated and experimentally validated. The developed system tools will be made available to researchers, SMEs and industry for practical applications. Following this project, a commercial platform for interpretation and analysis of complex omics data and for deriving and testing new hypotheses will be set up by the participating companies and academic partners. CanPathPro will enhance the competitive potential of the SMEs involved expanding in the field of biotechnology, personalised medicine and drug development and also provide new opportunities for other SMEs working in the field of bioinformatics and biomedical applications.
| ALACRIS THERANOSTICS GmbH | 3 414 976 € |
| Agencia Estatal Consejo Superior de Investigaciones Cientificas | 602 370 € |
| BIOGNOSYS AG | 0,00 € |
| Centre Europeen de Recherche en Biologie et Medecine | 1 052 103 € |
| Finovatis | 264 687 € |
| HELMHOLTZ ZENTRUM MUENCHEN DEUTSCHES FORSCHUNGSZENTRUM für GESUNDHEIT UND UMWELT GmbH | 751 461 € |
| 1 810 724 € | |
| RHEINISCHE FRIEDRICH-WILHELMS-UNIVERSITAT BONN | 300 000 € |
| Simula Research Laboratory AS | 782 901 € |
| Stichting HET Nederlands Kanker Instituut-Antoni Van Leeuwenhoek Ziekenhuis | 883 324 € |
https://cordis.europa.eu/project/id/686282
Cette annonce se réfère à une date antérieure et ne reflète pas nécessairement l’état actuel.
Les visualisations de "ALACRIS THERANOSTICS GmbH - Financement de l’UE (9 862 546 €) : Génération du prototype CanPath - une plateforme pour la modélisation prédictive des voies du cancer"
sont mis à disposition par
North Data
et peuvent être réutilisées selon les termes de la licence
Creative Commons CC-BY.
